Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Zealand Pharma - Execution framework for share buy-back program
Company announcement No. 15 / 2026 Zealand Pharma - Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a…
Zealand Pharma Announces Financial Results for the First Three Months of 2026
Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets, petrelintide and survodutide, and strong…
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
Company announcement No. 13 / 2026 Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program Robust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026 Financial strength to be further enhanced by…
Innocan Pharma LPT-CBD is featured in Pain Medicine News
The article highlights expert discussion presented at PAINWeek 2025 regarding Innocan's LPT-CBD. LPT-CBD is designed to enable prolonged CBD release into the bloodstream, enhance bioavailability, and support once-monthly subcutaneous…
Indian companies pledge to invest record $20.5 billion in US; pharma in focus
Indian companies have pledged to invest a record $20.5 billion in the United States, which includes $19.1 billion in pharmaceuticals, the US embassy said on Wednesday. The commitments were made during an investment summit in Maryland, US. According…
Health deserts, hospital windfalls, and a phalanx of pharma lobbyists: Inside the most controversial healthcare program you never heard of
Keith Harvey is CEO of Cook Area Health Services, better known as Scenic Rivers Health, a group of nonprofit medical and dental clinics in the northeast Minnesota hinterlands. Scenic Rivers Health struggles to make the most of a mysterious federal…
Ascendis Pharma A/S Q1 Earnings Call Highlights
Can BioMarin Stock Live Up to Wall Street's High Expectations? Ascendis Pharma A/S NASDAQ: ASND reported first-quarter 2026 results highlighted by the U.S. FDA approval of its third TransCon product, YUVIWEL, and continued growth across its rare…
Idaho to receive over $24M in opioid settlement with Purdue Pharma
Local News The Office of Idaho Attorney General Raúl Labrador said the settlement follows a nearly decade-long investigation into the company. BOISE, Idaho — The state of Idaho is set to receive nearly $24.5 million, part of a…
Vanguard Group Inc. Cuts Stake in Royalty Pharma PLC $RPRX
Vanguard Group Inc. reduced its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 9.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 9,934,612 shares of the biopharmaceutical company's…
Urogen Pharma Q1 Earnings Call Highlights
3 Bullish Biotech Stocks With Explosive Growth Trends Urogen Pharma NASDAQ: URGN reported first-quarter 2026 results that management said showed accelerating early momentum from the commercial launch of ZUSDURI, driven in part by the implementation…
Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up After Strong Earnings
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $45.30, but opened at $55.36. Zealand Pharma…
HC Wainwright Boosts Earnings Estimates for Nuvectis Pharma
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Investment analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Nuvectis Pharma in a research note issued on Tuesday, May 5th. HC Wainwright analyst J.
Royalty Pharma Q1 Earnings Call Highlights
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks Royalty Pharma NASDAQ: RPRX reported what executives described as a “strong start” to 2026, driven by double-digit growth in cash receipts, active capital deployment and a…
Athira Pharma (NASDAQ:LONA) Trading Down 2.2% - Should You Sell?
Athira Pharma, Inc. (NASDAQ:LONA - Get Free Report) fell 2.2% during trading on Wednesday. The company traded as low as $9.32 and last traded at $9.42. 19,694 shares traded hands during trading, a decline of 48% from the average session volume of…
Urogen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Oppenheimer Analyst Says
Urogen Pharma (NASDAQ:URGN - Get Free Report) had its target price lifted by investment analysts at Oppenheimer from $34.00 to $40.00 in a report issued on Thursday, Marketbeat Ratings reports. The brokerage currently has an 'outperform' rating on…
Receive a Daily briefing on Pharma Industry News
Get Started